MedWell Laboratories
Anti-Inflammatory Drugs to Manage Chronic Inflammation
Company Overview
Snapshot
Founded in January 2009 by Taher Nassar, MedWell Laboratories operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on the development of anti-inflammatory drugs.
Business overview
MedWell Laboratories is a pharmaceutical company developing anti-inflammatory drugs to manage mild to moderate chronic inflammatory disorders. The company's proprietary technology focuses on creating drugs that act as selective inhibitors of both COX-2 and 5-LOX enzymes, utilizing natural fatty acids and amino acids. MedWell Laboratories serves the pharmaceutical industry, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is MedWell Laboratories' primary focus?
- MedWell Laboratories is focused on developing anti-inflammatory drugs to address mild to moderate chronic inflammatory disorders, offering an alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs).
- When was MedWell Laboratories founded?
- MedWell Laboratories was founded in January 2009.
- Who is the founder of MedWell Laboratories?
- Taher Nassar is a co-founder of MedWell Laboratories.
- What technology underpins MedWell Laboratories' drug development?
- MedWell Laboratories develops anti-inflammatory drugs based on proprietary technology that enables selective inhibition of both COX-2 and 5-LOX enzymes, utilizing natural fatty acids and amino acids.
- What is the current status of MedWell Laboratories?
- MedWell Laboratories is currently in a Non Active status as of December 2016 and is in the Pre-Funding stage of development.